6/11/2013

Following a $500 million settlement with the US FDA over selling adulterated drugs, the generic-drug firm Ranbaxy Laboratories is facing a public-interest lawsuit in India to shutter the two Indian manufacturing plants involved in the FDA settlement and launch a companywide investigation. The lawsuit alleges "outright fraud, in which the company knowingly sold substandard drugs around the world." Ranbaxy disputed the allegations, stating that all of its products are safe and effective.

Full Story:
BioSpectrum Asia

Related Summaries